Unravelling B cell and antibody responses to cancer The contributions of B cells and antibodies remain insufficiently understood. Despite expressing antibodies, patients’ immune systems are mostly ineffective in restricting cancer growth. We have developed novel approaches aimed at understanding and activating immune responses to melanoma with particular focus on B cell responses and the antibodies they produce. Our approach encompasses: a) elucidating antibody mechanisms of action in disease-relevant models; b) dissecting humoral immune responses and mechanisms that may impair anti-tumour immunity and cytotoxic antibodies from eradicating tumours in patients; c) designing antibodies with potent effector functions. We are able to discover and evaluate novel antibodies for tumour specificity, we examine their ability and mechanisms by which they target and kill tumour cells, and we evaluate their potential efficacy as diagnostic and/or therapeutic agents.